Cited by 530Schizophrenia research and treatmentNeuroscience and Neuropharmacology ResearchTreatment of Major Depression

The DOI matches its Crossref record; 307 of the 307 references it cites were found in a registry or an index.

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

Open access

Krystal, John H., D'Souza, D. Cyril, Mathalon, Daniel, Perry, Edward, Belger, Aysenil, Hoffman, Ralph·2003·Psychopharmacology

DOI 10.1007/s00213-003-1582-z

Open this paper in CoChat — free account

Abstract

There is an urgent need to improve the pharmacotherapy of schizophrenia despite the introduction of important new medications. New treatment insights may come from appreciating the therapeutic implications of model psychoses. In particular, basic and clinical studies have employed the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, ketamine, as a probe of NMDA receptor contributions to cognition and behavior. These studies illustrate a translational neuroscience approach for probing mechanistic hypotheses related to the neurobiology and treatment of schizophrenia and other disorders. Two particular pathophysiologic themes associated with schizophrenia, the disturbance of cortical connectivity and the disinhibition of glutamatergic activity may be modeled by the administration of NMDA receptor antagonists. The purpose of this review is to consider the possibility that agents that attenuate these two components of NMDA receptor antagonist response may play complementary roles in the treatment of schizophrenia.

Integrity signals

Registry

Crossref · 10.1007/s00213-003-1582-z

Cites

307 of 307 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Epigenetic Regulations of GABAergic Neurotransmission: Relevance for Neurological Disorders and Epigenetic Therapy
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,951
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Self-citation
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,182
PHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORS
Conn, P. J., & Pin, J. (1997) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.205 · Cited by 3,083
Physiologic Dysfunction of Dorsolateral Prefrontal Cortex in Schizophrenia
Weinberger, D. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800020020004 · Cited by 2,025
Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Neuregulin 1 and Susceptibility to Schizophrenia
Stefánsson, H., Pétursson, H., Sigurðsson, E., Steinthórsdóttir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., Brynjolfsson, J., Gunnarsdottir, S., Ivarsson, O., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342734 · Cited by 1,671
Decreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636
Glial reduction in the subgenual prefrontal cortex in mood disorders
Öngür, D., Drevets, W. C., & Price, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13290 · Cited by 1,525
Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression∗∗See accompanying Editorial, in this issue.
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,352
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Self-citation
THE BRAIN’S RECORD OF AUDITORY AND VISUAL EXPERIENCE: A FINAL SUMMARY AND DISCUSSION
PENFIELD, W., & PEROT, P. (1963) · Brain · doi:10.1093/brain/86.4.595 · Cited by 1,230
Risperidone in the treatment of schizophrenia
Marder, S. R., & Meibach, R. C. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,194
Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia
Hakak, Y., Walker, J. R., Li, C., Wong, W. H., Davis, K. L., Buxbaum, J. D., Haroutunian, V., & Fienberg, A. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081071198 · Cited by 1,192
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154 · cited 2×
“In schizophrenic patients, particularly those with recent psychotic exacerbations, psy- chotic symptoms are associated with dopaminergic hyperactivity (Abi-Dargham et al. 2000; Breier et al. 1997b; Laruelle et al. 1996, 1999).”
BackgroundInfluential
Experience-Induced Neurogenesis in the Senescent Dentate Gyrus
Kempermann, G., Kuhn, H. G., & Gage, F. H. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-09-03206.1998 · Cited by 1,150
Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia
Saykin, A. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020048005 · Cited by 1,086
GABAergic Interneurons Implications for Understanding Schizophrenia and Bipolar Disorder
Benes, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00225-1 · Cited by 1,082
Coupling of mGluR/Homer and PSD-95 Complexes by the Shank Family of Postsynaptic Density Proteins
Tu, J. C., Xiao, B., Naisbitt, S. R., Yuan, J. P., Petralia, R. S., Brakeman, P., Doan, A., Aakalu, V. K., Lanahan, A. A., Sheng, M., et al. (1999) · Neuron · doi:10.1016/s0896-6273(00)80810-7 · Cited by 1,079
Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors
Kramer, M. S., Cutler, N. R., Feighner, J. P., Shrivastava, R. K., Carman, J. S., Sramek, J. J., Reines, S. A., Liu, G. F., Snavely, D. B., Wyatt-Knowles, E. S., et al. (1998) · Science · doi:10.1126/science.281.5383.1640 · Cited by 1,071
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006
Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics.
Akbarian, S. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950160008002 · Cited by 1,002
Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia
Lahti, A., Koffel, B., Laporte, D., & Tamminga, C. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00131-i · Cited by 965
Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors
Burris, K. D., Molski, T. F. P., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 924
Study of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
The reduced neuropil hypothesis: a circuit based model of schizophrenia
Selemon, L. D., & Goldman-Rakic, P. S. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00281-9 · Cited by 909
A functional neuroanatomy of hallucinations in schizophrenia
Silbersweig, D. A., Stern, E., Frith, C., Cahill, C., Holmes, A., Grootoonk, S., Seaward, J., McKenna, P., Chua, S. E., Schnorr, L., et al. (1995) · Nature · doi:10.1038/378176a0 · Cited by 906 · cited 1×
“…with direct electrical stimulation of brain regions associated with the auditory function (Gloor 1990; Halgren et al. 1978; Penfield and Perot 1963) and the regional cortical activation patterns during auditory hallucinations (Dierks et al. 1999; Silbersweig et al. 1995; Shergill et al. 2000).”
Background
Deficits in Small Interneurons in Prefrontal and Cingulate Cortices of Schizophrenic and Schizoaffective Patients
Benes, F. M. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810350036005 · Cited by 891
Synaptic basis of cortical persistent activity: the importance of NMDA receptors to working memory
Wang, X.-J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-21-09587.1999 · Cited by 859
Genetic and physiological data implicating the new human gene G72 and the gene for d -amino acid oxidase in schizophrenia
Chumakov, I. M., BLUMENFELD, M. L., Guerassimenko, O., Cavarec, L., Palicio, M., Abderrahim, H., Bougueleret, L., Barry, C., Tanaka, H., Rosa, P. L., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412499 · Cited by 834
D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release
Schell, M. J., Molliver, M. E., & Snyder, S. H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3948 · Cited by 832
Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia
Thompson, P. M., Vidal, C., Giedd, J. N., Gochman, P., Blumenthal, J., Nicolson, R., Toga, A. W., & Rapoport, J. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201243998 · Cited by 812
Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
Arvanitis, L. A., & Miller, B. G. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00190-x · Cited by 801
A decrease of reelin expression as a putative vulnerability factor in schizophrenia
Impagnatiello, F., Guidotti, A. R., Pesold, C., Dwivedi, Y., Caruncho, H. J., Pisu, M. G., Uzunov, D. P., Smalheiser, N. R., Davis, J. M., Pandey, G. N., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15718 · Cited by 762
Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man
Domino, E. F., Chodoff, P., & Corssen, G. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563279 · Cited by 753
Activation of Heschl’s Gyrus during Auditory Hallucinations
Dierks, T., Linden, D. E. J., Jandl, M., Formisano, E., Goebel, R., Lanfermann, H., & Singer, W. (1999) · Neuron · doi:10.1016/s0896-6273(00)80715-1 · Cited by 752
Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective
Young, D., Lawlor, P. A., Leone, P., Dragunow, M., & During, M. J. (1999) · Nature Medicine · doi:10.1038/7449 · Cited by 745
Increased dopamine transmission in schizophrenia: relationship to illness phases
Laruelle, M. A., Abi‐Dargham, A., Gil, R. B., Kegeles, L. S., & Innis, R. B. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00067-0 · Cited by 724
Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia
Kapur, S., Zipursky, R. B., & Remington, G. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.286 · Cited by 711
Ketamine: an update on the first twenty-five years of clinical experience
Reich, D. L., & Silvay, G. (1989) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/bf03011442 · Cited by 707
Decreased Glutamic Acid Decarboxylase67 Messenger RNA Expression in a Subset of Prefrontal Cortical γ-Aminobutyric Acid Neurons in Subjects With Schizophrenia
Volk, D. W., Austin, M. C., Pierri, J. N., Sampson, A. R., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.237 · Cited by 697
Unveiling the Functions of Presynaptic Metabotropic Glutamate Receptors in the Central Nervous System
Schoepp, D. D. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29296-x · Cited by 693
Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics
Malhotra, A. K. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00036-5 · Cited by 681
Altered Distribution of Nicotinamide-Adenine Dinucleotide Phosphate—Diaphorase Cells in Frontal Lobe of Schizophrenics Implies Disturbances of Cortical Development
Akbarian, S. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820150007001 · Cited by 680
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y., & Chong, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 676
Effects of Ketamine in Normal and Schizophrenic Volunteers
Lahti, A. C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00243-3 · Cited by 674
Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins
Weinberger, D. R., Berman, K. F., Suddath, R. L., & Torrey, E. F. (1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.7.890 · Cited by 669
Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging
Shergill, S. S., Brammer, M. J., Williams, S. C. R., Murray, R. M., & McGuire, P. K. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.11.1033 · Cited by 666 · cited 3×
“Even when patients as a group had normal or reduced metabolism, metabolic rates increased with increasing severity of positive symptoms (Gur et al. 1987), particularly auditory hallucinations (Dierks et al. 1999; Shergill et al. 2000).”
Background
Gamma frequency-range abnormalities to auditory stimulation in schizophrenia
Kwon, J. S., O'Donnell, B. F., Wallenstein, G. V., Greene, R. W., Hirayasu, Y., Nestor, P. G., Hasselmo, M. E., Potts, G. F., Shenton, M. E., & McCarley, R. W. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.11.1001 · Cited by 654
Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder
Kane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., ZIMBROFF, D. L., & Ali, M. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0903 · Cited by 624
Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naïve patients.
Andreasen, N., O'Leary, D. S., Flaum, M., Nopoulos, P., Watkins, G. L., Ponto, L. B., & Hichwa, R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)08258-x · Cited by 623
Selective Deficits in Prefrontal Cortex Function in Medication-Naive Patients With Schizophrenia
Barch, D. M., Carter, C. S., Braver, T. S., Sabb, F. W., MacDonald, A. W., Noll, D. C., & Cohen, J. D. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.3.280 · Cited by 615
Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis
Newcomer, J. W. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00067-0 · Cited by 611
Increased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Opposite effects of high and low frequency rTMS on regional brain activity in depressed patients
Speer, A. M., Kimbrell, T. A., Wassermann, E. M., Repella, J. D., Willis, M. W., Herscovitch, P., & Post, R. M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01065-9 · Cited by 587
A neurohistological correlate of schizophrenia.
Kovelman, J. A., & Scheibel, A. B. (1984) · PubMed · Cited by 582
Rapid, experience-dependent expression of synaptic NMDA receptors in visual cortex in vivo
Quinlan, E. M., Philpot, B. D., Huganir, R. L., & Bear, M. F. (1999) · Nature Neuroscience · doi:10.1038/7263 · Cited by 579
MENTAL PHENOMENA EVOKED BY ELECTRICAL STIMULATION OF THE HUMAN HIPPOCAMPAL FORMATION AND AMYGDALA
Halgren, E., WALTER, R. D., Cherlow, D. G., & Crandall, P. H. (1978) · Brain · doi:10.1093/brain/101.1.83 · Cited by 573
D-serine added to antipsychotics for the treatment of schizophrenia
Tsai, G. E., Yang, P., Chung, L.-C., LANGE, N. D., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00279-0 · Cited by 572
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
Krystal, J. H., Sanacora, G., Blumberg, H., Anand, A., Charney, D. S., Marek, G., Epperson, C. N., Goddard, A., & Mason, G. F. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001021 · Cited by 553
Self-citation
Neuronal and Glial Somal Size in the Prefrontal Cortex: A Postmortem Morphometric Study of Schizophrenia and Huntington Disease
Rajkowska, G., Selemon, L. D., & Goldman-Rakic, P. S. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.3.215 · Cited by 537
Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations
Lawrie, S. M., Buechel, C., Whalley, H. C., Frith, C. D., Friston, K. J., & Johnstone, E. C. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01316-1 · Cited by 529
Transcranial Magnetic Stimulation of Left Temporoparietal Cortex and Medication-Resistant Auditory Hallucinations
Hoffman, R. E., Hawkins, K. A., Gueorguieva, R. V., Boutros, N. N., Rachid, F., Carroll, K. M., & Krystal, J. H. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.49 · Cited by 520
Self-citation
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck, R. A., Cramer, J. A., Xu, W., Thomas, J. V., Henderson, W., Frisman, L. K., Fye, C. L., & Charney, D. S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371202 · Cited by 514
Evidence for Abnormal Cortical Functional Connectivity During Working Memory in Schizophrenia
Meyer‐Lindenberg, A., Poline, J., Kohn, P. D., Holt, J. L., Egan, M. F., Weinberger, D. R., & Berman, K. F. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1809 · Cited by 511
The Relation between Funding by the National Institutes of Health and the Burden of Disease
Gross, C. P., Anderson, G. F., & Powe, N. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906173402406 · Cited by 509
The anatomy of conscious vision: an fMRI study of visual hallucinations
Ffytche, D. H., Howard, R. J., Brammer, M. J., David, A. S., Woodruff, P. W. R., & Williams, S. (1998) · Nature Neuroscience · doi:10.1038/3738 · Cited by 504
Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage
Werner, P., Pitt, D., & Raine, C. S. (2001) · Annals of Neurology · doi:10.1002/ana.1077 · Cited by 488
Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia
Heresco‐Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G. S., & Lichtenstein, M. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.29 · Cited by 487
NMDA-dependent modulation of CA1 local circuit inhibition
Grunze, H., Rainnie, D., Hasselmo, M., Barkai, E., Hearn, E., McCarley, R., & Greene, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-06-02034.1996 · Cited by 467
Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains
Tsai, G. E. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950220039008 · Cited by 455
Uncinate Fasciculus Findings in Schizophrenia: A Magnetic Resonance Diffusion Tensor Imaging Study
Kubicki, M. R., Westin, C., Maier, S. E., Frumin, M., Nestor, P. G., Salisbury, D. F., Kikinis, R., Jolesz, F. A., McCarley, R. W., & Shenton, M. E. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.813 · Cited by 454
Distorted Distribution of Nicotinamide-Adenine Dinucleotide Phosphate—Diaphorase Neurons in Temporal Lobe of Schizophrenics Implies Anomalous Cortical Development
Akbarian, S. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820150016002 · Cited by 452
Compromised White Matter Tract Integrity in Schizophrenia Inferred From Diffusion Tensor Imaging
Lim, K. O., Hedehus, M., Moseley, M. E., de Crespigny, A. J., Sullivan, E. V., & Pfefferbaum, A. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.4.367 · Cited by 447
A role for NMDA-receptor channels in working memory
Lisman, J. E., Fellous, J., & Wang, X. (1998) · Nature Neuroscience · doi:10.1038/1086 · Cited by 438
A Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics in Patients With Schizophrenia
GOFF, D. C., Tsai, G. E., Levitt, J. J., AMICO, E. T., Manoach, D. S., Schoenfeld, D., Hayden, D. L., McCarley, R. W., & Coyle, J. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.21 · Cited by 436
Ketamine activates psychosis and alters limbic blood flow in schizophrenia
Lahti, A. C., Holcomb, H. H., Medoff, D. R., & Tamminga, C. A. (1995) · Neuroreport · doi:10.1097/00001756-199504190-00011 · Cited by 434
Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors.
Øye, I., Paulsen, O., & Maurset, A. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11430-4 · Cited by 430
Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics
BEASLEY, C., & REYNOLDS, G. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00122-3 · Cited by 426
Attenuation of the Neuropsychiatric Effects of Ketamine With Lamotrigine: Support for Hyperglutamatergic Effects of N-methyl-D-aspartate Receptor Antagonists
Anand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426
Self-citation
Activation of Metabotropic Glutamate Receptor 5 Has Direct Excitatory Effects and Potentiates NMDA Receptor Currents in Neurons of the Subthalamic Nucleus
Awad, H., Hubert, G. W., Smith, Y., Levey, A. I., & Conn, P. J. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-21-07871.2000 · Cited by 423
Modulation of N -methyl- d -aspartate receptor function by glycine transport
Bergeron, R., Meyer, T. M., Coyle, J. T., & Greene, R. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15730 · Cited by 418
Glutamate receptor expression in schizophrenic brain
Meador‐Woodruff, J. H. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00044-2 · Cited by 416
d-Serine as a Neuromodulator: Regional and Developmental Localizations in Rat Brain Glia Resemble NMDA Receptors
Schell, M. J., Brady Jr., R. O., Molliver, M. E., & Snyder, S. H. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01604.1997 · Cited by 415 · cited 2×
“…another endogenous glycineB receptor agonist, dserine, to enhance NMDA receptor function in an activity-dependent manner (Ivanovic et al. 1998; Schell et al. 1997). d-Serine may be released into synapses by glia in response to a-amino-3-hydroxy-5-methylisoxazolepropionic acid (AMPA) glutamate…”
Background
Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)
Vollenweider, F. X., Leenders, K. L., Øye, I., Hell, D., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00042-9 · Cited by 413
Intramuscular Ketamine for Pediatric Sedation in the Emergency Department: Safety Profile in 1,022 Cases
Green, S. M., Rothrock, S. G., Lynch, E. L., Ho, M., Harris, T., Hestdalen, R., Hopkins, G. A., Garrett, W., & Westcott, K. (1998) · Annals of Emergency Medicine · doi:10.1016/s0196-0644(98)70226-4 · Cited by 409
Destruction and Creation of Spatial Tuning by Disinhibition: GABAABlockade of Prefrontal Cortical Neurons Engaged by Working Memory
Rao, S. G., Williams, G. V., & Goldman-Rakic, P. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-01-00485.2000 · Cited by 407
Maldistribution of Interstitial Neurons in Prefrontal White Matter of the Brains of Schizophrenic Patients
Akbarian, S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830050061010 · Cited by 397
Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
Green, M. F., Marshall, B. D., Wirshing, W. C., Ames, D., Marder, S. R., McGurk, S. R., Kern, R. S., & Mintz, J. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.799 · Cited by 397
Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1α, mGluR2 and mGluR5, relative to neurotransmitter release sites
Luján, R., Roberts, J. D. B., Shigemoto, R., Ohishi, H., & Somogyi, P. (1997) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(97)00051-3 · Cited by 395
Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.805 · Cited by 392
Schizophrenia and Glutamatergic Transmission
Tamminga, C. A. (1998) · Critical Reviews in Neurobiology · doi:10.1615/critrevneurobiol.v12.i1-2.20 · Cited by 382
Expression Mechanisms Underlying NMDA Receptor‐Dependent Long‐Term Potentiation
Nicoll, R. A., & Malenka, R. C. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb11320.x · Cited by 378
EXPERIENTIAL PHENOMENA OF TEMPORAL LOBE EPILEPSY
GLOOR, P. (1990) · Brain · doi:10.1093/brain/113.6.1673 · Cited by 376
Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder A 6-Week Placebo-Controlled Trial
Daniel, D. G. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00090-6 · Cited by 376
Dopamine D1 Receptor-Dependent Trafficking of Striatal NMDA Glutamate Receptors to the Postsynaptic Membrane
Dunah, A. W., & Standaert, D. G. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-15-05546.2001 · Cited by 374
Psychedelic Effects of Ketamine in Healthy Volunteers
Bowdle, A. T., Radant, A. D., Cowley, D. S., Kharasch, E. D., Strassman, R. J., & Roy‐Byrne, P. (1998) · Anesthesiology · doi:10.1097/00000542-199801000-00015 · Cited by 370
MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia
Buchsbaum, M., Tang, C. Y., Peled, S., Gudbjartsson, H., Lu, D.-F., Hazlett, E., Downhill, J., Haznedar, M., Fallon, J., & Atlas, S. (1998) · NeuroReport · doi:10.1097/00001756-199802160-00013 · Cited by 369
Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics
Benes, F., Vincent, S. L., Alsterberg, G., Bird, E. D., & SanGiovanni, J. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-03-00924.1992 · Cited by 365
Amelioration of negative symptoms in schizophrenia by glycine
Javitt, D. C., Zylberman, I., Zukin, S. R., Heresco‐Levy, U., & Lindenmayer, J. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1234 · Cited by 353
Neurocognitive Enhancement Therapy With Work Therapy
Bell, M. D., BRYSON, G. J., Greig, T. C., Corcoran, C., & Wexler, B. E. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.8.763 · Cited by 352
Differential effects of enrichment on learning and memory function in NR2B transgenic mice
Tang, Y., Wang, H., Feng, R., Kyin, M., & Tsien, J. Z. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00122-8 · Cited by 343
A systems model of altered consciousness: integrating natural and drug-induced psychoses
Vollenweider, F. X., & Geyer, M. A. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00646-3 · Cited by 339
Isodirectional Tuning of Adjacent Interneurons and Pyramidal Cells During Working Memory: Evidence for Microcolumnar Organization in PFC
Rao, S. G., Williams, G. V., & Goldman, P. S. (1999) · Journal of Neurophysiology · doi:10.1152/jn.1999.81.4.1903 · Cited by 339
Natural History of Schizophrenia Subtypes
Fenton, W. S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810350018003 · Cited by 338
Symptoms, Cognitive Functioning, and Adaptive Skills in Geriatric Patients With Lifelong Schizophrenia: A Comparison Across Treatment Sites
Harvey, P. D., Howanitz, E. M., Parrella, M. J., WHITE, L. E., Davidson, M., Mohs, R. C., Hoblyn, J. C., & Davis, K. L. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.8.1080 · Cited by 337
A Dopamine/D1 Receptor/Protein Kinase A/Dopamine- and cAMP-Regulated Phosphoprotein (Mr32 kDa)/Protein Phosphatase-1 Pathway Regulates Dephosphorylation of the NMDA Receptor
Snyder, G. L., Fienberg, A. A., Huganir, R. L., & Greengard, P. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-24-10297.1998 · Cited by 336
Reduced communication between frontal and temporal lobes during talking in schizophrenia
Ford, J. M., Mathalon, D. H., Whitfield‐Gabrieli, S., Faustman, W. O., & Roth, W. T. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01335-x · Cited by 332
Self-citation
Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity.
Glantz, L., & Lewis, D. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830220065010 · Cited by 328
N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability
Krystal, J. H., Petrakis, I. L., Mason, G. F., Trevisan, L. A., & D’Souza, D. C. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00054-8 · Cited by 318
Self-citation
Trait and state aspects of p300 amplitude reduction in schizophrenia: a retrospective longitudinal study
Mathalon, D. H., Ford, J. M., & Adolf Pfefferbaum, A. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00277-2 · Cited by 317
Self-citation
Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions
Arnold, S. E., Franz, B. R., Gur, R. C., Gur, R. E., Shapiro, R. M., Moberg, P. J., & Trojanowski, J. Q. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.5.738 · Cited by 310
KETAMINE INFUSIONS: PHARMACOKINETICS AND CLINICAL EFFECTS
Idvall, J., Ahlgren, I., Aronsen, K. F., & Stenberg, P. B. (1979) · British Journal of Anaesthesia · doi:10.1093/bja/51.12.1167 · Cited by 306
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group
ZIMBROFF, D. L., Kane, J. M., Tamminga, C. A., Daniel, D. G., Mack, R. J., Wozniak, P. J., Sebree, T. B., Wallin, B., & Kashkin, K. B. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.782 · Cited by 306
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
Tollefson, G. D., & Sanger, T. M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.466 · Cited by 304
Neurophysiological evidence of corollary discharge dysfunction in schizophrenia
Ford, J. M., Mathalon, D. H., Heinks, T., Kalba, S., Faustman, W. O., & Roth, W. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2069 · Cited by 304
Self-citation
Severity of symptoms in chronically institutionalized geriatric schizophrenic patients
Davidson, M., Harvey, P. D., Powchik, P., Parrella, M., WHITE, L. E., Knobler, H. Y., LOSONCZY, M. F., Keefe, R. S. E., Katz, S., & Frecska, E. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.197 · Cited by 303
Alterations in Chandelier Neuron Axon Terminals in the Prefrontal Cortex of Schizophrenic Subjects
Pierri, J. N., Chaudry, A. S., Woo, T.-U. W., & Lewis, D. A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1709 · Cited by 294
Mechanisms of Calcium Influx into Hippocampal Spines: Heterogeneity among Spines, Coincidence Detection by NMDA Receptors, and Optical Quantal Analysis
Yuste, R., Majewska, A. K., Cash, S. S., & Denk, W. T. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-06-01976.1999 · Cited by 288
Slow Transcranial Magnetic Stimulation, Long-Term Depotentiation, and Brain Hyperexcitability Disorders
Hoffman, R. E., & Çavuş, I. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1093 · Cited by 286
Self-citation
Cognitive Correlates of Job Tenure Among Patients With Severe Mental Illness
Gold, J. M., Goldberg, R. W., McNary, S. W., Dixon, L. B., & Lehman, A. F. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.8.1395 · Cited by 285
What Are the Right Targets for Psychopharmacology?
Hyman, S. E., & Fenton, W. S. (2003) · Science · doi:10.1126/science.1077141 · Cited by 282
The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance
Buchanan, R. W., Holstein, C., & Breier, A. F. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90082-5 · Cited by 281
Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects
Benes, F. M., Vincent, S. L., Marie, A. S., & Khan, Y. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00328-4 · Cited by 276
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects
Krystal, J. H., Abi-Saab, W., Perry, E., D’Souza, D. C., Liu, N., Gueorguieva, R., McDougall, L., Hunsberger, T., Belger, A., Levine, L., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-004-1982-8 · Cited by 272
Self-citation
Reciprocal Alterations in Pre- and Postsynaptic Inhibitory Markers at Chandelier Cell Inputs to Pyramidal Neurons in Schizophrenia
Volk, D. W. (2002) · Cerebral Cortex · doi:10.1093/cercor/12.10.1063 · Cited by 264
Design, Synthesis, and Biological Activity of a Potent Inhibitor of the Neuropeptidase N-Acetylated α-Linked Acidic Dipeptidase
Jackson, P., Cole, D. C., Slusher, B. S., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950801q · Cited by 259
Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia
Lewis, D. A., Pierri, J. N., Volk, D. W., Melchitzky, D. S., & Woo, T.-U. W. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00061-x · Cited by 258
GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia
Lewis, D. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00042-9 · Cited by 257
Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia
Heresco‐Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Horowitz, A., & Kelly, D. (1996) · The British Journal of Psychiatry · doi:10.1192/bjp.169.5.610 · Cited by 255
NMDA receptor regulation of memory and behavior in humans
Newcomer, J. W., & Krystal, J. H. (2001) · Hippocampus · doi:10.1002/hipo.1069 · Cited by 244
Self-citation
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
GOFF, D. C., Tsai, G. E., Manoach, D. S., & Coyle, J. T. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1213 · Cited by 243
Interactive effects of subanesthetic ketamine and haloperidol in healthy humans
Krystal, J. H., D’Souza, D. C., Karper, L. P., Bennett, A., Abi‐Dargham, A., Abi‐Saab, D., Cassello, K., Bowers, M. B., Vegso, S., Heninger, G. R., et al. (1999) · Psychopharmacology · doi:10.1007/s002130051049 · Cited by 243
Self-citation
Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of Schizophrenia
Casey, D. E., Daniel, D. G., Wassef, A. A., Tracy, K. A., Wozniak, P., & Sommerville, K. W. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300023 · Cited by 232
NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders
Krystal, J. H., D’Souza, C., Petrakis, I. L., Belger, A., Berman, R., Charney, D. S., Abi‐Saab, W., & Madonick, S. H. (1999) · Harvard Review of Psychiatry · doi:10.3109/hrp.7.3.125 · Cited by 232
Self-citation
Measurement of Glutamate and Glutamine in the Medial Prefrontal Cortex of Never-Treated Schizophrenic Patients and Healthy Controls by Proton Magnetic Resonance Spectroscopy
Bartha, R. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830220085012 · Cited by 230
d- Serine Added to Clozapine for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chung, L.-C., Tsai, I.-C., Tsai, C.-W., & Coyle, J. T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1822 · Cited by 227
Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia
Eastwood, S. L., Burnet, P. W. J., & Harrison, P. J. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00586-t · Cited by 223
SR 142801, The first potent non-peptide antagonist of the tachykinin NK3 receptor
Emonds‐Alt, X., Bichon, D., Ducoux, J.-P., Héaulme, M., Miloux, B., Poncelet, M., Proietto, V., Broeck, D. V., Vilain, P., Neliat, G., et al. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00413-m · Cited by 217
The density and spatial distribution of gabaergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia
Cotter, D., Landau, S., Beasley, C. L., Stevenson, R. N., Chana, G., MacMillan, L., & Everall, I. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01243-4 · Cited by 211
A Placebo-Controlled Pilot Study of the Ampakine CX516 Added to Clozapine in Schizophrenia
GOFF, D. C., Leahy, L., Berman, I., Posever, T. A., Herz, L. R., Leon, A. C., Johnson, S. A., & LYNCH, G. S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00005 · Cited by 209
The NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls
Abi-Saab, W., D'Souza, D., Moghaddam, B., & Krystal, J. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979354 · Cited by 208
Self-citation
Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia.
(1992) · PubMed Central · Cited by 207
Regional Brain Function in Schizophrenia
Gur, R. E. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800140021003 · Cited by 206
Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients
Siegel, B. V., Buchsbaum, M. S., Bunney, W. E., Gottschalk, L. A., Haier, R. J., Lohr, J. B., Lottenberg, S., Najafi, A., Nuechterlein, K. H., & Potkin, S. G. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.9.1325 · Cited by 201
The Effects of a Selective D4 Dopamine Receptor Antagonist (L-745,870) in Acutely Psychotic Inpatients With Schizophrenia
Kramer, M. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830180085011 · Cited by 201
Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications
Stefani, A., Spadoni, F., Siniscalchi, A., & Bernardi, G. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00265-8 · Cited by 200
Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia
Cleghorn, J. M., Garnett, E. S., Nahmias, C., Firnau, G., Brown, G. M., Kaplan, R. D., Szechtman, H., & Szechtman, B. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90040-1 · Cited by 197
Reduced GABA uptake sites in the temporal lobe in schizophrenia
Simpson, M. D. C., Slater, P., Deakin, J. F. W., Royston, M. C., & Skan, W. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90819-7 · Cited by 193
Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons
Woo, T., Miller, J. L., & Lewis, D. A. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.7.1013 · Cited by 191
Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial
Tiihonen, J., Hallikainen, T., Ryynänen, O., Repo‐Tiihonen, E., Kotilainen, I., Eronen, M., Toivonen, P., Wahlbeck, K., & Putkonen, A. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00524-9 · Cited by 191
Expression of Excitatory Amino Acid Transporter Transcripts in the Thalamus of Subjects With Schizophrenia
Smith, R. E., Haroutunian, V. H., Davis, K. L., & Meador‐Woodruff, J. H. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1393 · Cited by 190
Local circuit neurons of the prefrontal cortex in schizophrenia: selective increase in the density of calbindin-immunoreactive neurons
DAVISS, S. R., & Lewis, D. A. (1995) · Psychiatry Research · doi:10.1016/0165-1781(95)02720-3 · Cited by 187
Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans
Krystal, J. H., Karper, L. P., Bennett, A., D’Souza, D. C., Abi‐Dargham, A., Morrissey, K., Abi‐Saab, D., Bremner, J. D., Bowers, M. B., Suckow, R. F., et al. (1998) · Psychopharmacology · doi:10.1007/s002130050503 · Cited by 184
Self-citation
"Psychedelic" Experiences in Acute Psychoses
Bowers, M. B. (1966) · Archives of General Psychiatry · doi:10.1001/archpsyc.1966.01730150016003 · Cited by 183
D-cycloserine added to clozapine for patients with schizophrenia
GOFF, D. C., Tsai, G. E., Manoach, D. S., Flood, J. G., Darby, D., & Coyle, J. T. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1628 · Cited by 182
Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABAA receptor α-1 subunit messenger RNA and human GABA transporter-1 (hGAT-1) messenger RNA expression
Ohnuma, T., Augood, S. J., Arai, H., McKenna, P. J., & Emson, P. C. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00189-x · Cited by 182
Association Between Smaller Left Posterior Superior Temporal Gyrus Volume on Magnetic Resonance Imaging and Smaller Left Temporal P300 Amplitude in First-Episode Schizophrenia
McCarley, R. W., Salisbury, D. F., Hirayasu, Y., Yurgelun-Todd, D. A., Tohen, M. F., Zarate, C. A., Kikinis, R., Jolesz, F. A., & Shenton, M. E. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.4.321 · Cited by 182
Gamma activity in schizophrenia: evidence of impaired network binding?
Haig, A. R., Gordon, E., Pascalis, V. D., Meares, R. A., Bahramali, H., & Harris, A. W. F. (2000) · Clinical Neurophysiology · doi:10.1016/s1388-2457(00)00347-3 · Cited by 176
Pharmacokinetics of ketamine in man.
Wieber, J., Gugler, R., Hengstmann, J. H., & Dengler, H. J. (1975) · PubMed · Cited by 176
The Nagging Question of the Function ofN-Acetylaspartylglutamate
Coyle, J. T. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0153 · Cited by 173
Prefrontal and temporal blood flow in schizophrenia: resting and activation technetium-99m-HMPAO SPECT patterns in young neuroleptic-naive patients with acute disease.
Catafau, A., Parellada, E., Lomeña, F. J., Bernardo, M., Pavı́a, J., Ros, D., SETOAIN, J., & González-Monclús, E. (1994) · PubMed · Cited by 173
Preliminary evidence of improved verbal working memory performance and normalization of task-related frontal lobe activation in schizophrenia following cognitive exercises
Wexler, B. E., Anderson, M., Fulbright, R. K., & Gore, J. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.10.1694 · Cited by 172
Brain Activations in Schizophrenia During a Graded Memory Task Studied With Functional Neuroimaging
Fletcher, P. C., McKenna, P. J., Frith, C., Grasby, P. M., Friston, K. J., & Dolan, R. J. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.11.1001 · Cited by 172
Placebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia
Evins, A. E., Fitzgerald, S. M., Wine, L., Rosselli, R., & GOFF, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.826 · Cited by 172
Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.
Essock, S. M., Hargreaves, W. A., Covell, N. H., & Goethe, J. (1996) · PubMed · Cited by 169
Decreased functional connectivity of EEG theta-frequency activity in first-episode, neuroleptic-naıve patients with schizophrenia: preliminary results
Koenig, T. W., Lehmann, D., Saito, N. H., Kuginuki, T., Kinoshita, T., & Koukkou, M. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00154-7 · Cited by 169
Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors.
Stockmeier, C. A., DiCarlo, J., Zhang, Y., Thompson, P. A., & Meltzer, H. Y. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39339-0 · Cited by 169
Control of NMDA Receptor Activation by a Glycine Transporter Co-Expressed inXenopusOocytes
Supplisson, S., & Bergman, C. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-12-04580.1997 · Cited by 168
Prefrontal Cortex and Schizophrenia
Wible, C. G. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950160029007 · Cited by 167
Dose-Related Ethanol-like Effects of the NMDA Antagonist, Ketamine, in Recently Detoxified Alcoholics
Krystal, J. H., Petrakis, I. L., Webb, E., Cooney, N. L., Karper, L. P., Namanworth, S. N., Stetson, P. L., Trevisan, L. A., & Charney, D. S. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.4.354 · Cited by 166
Self-citation
Work Rehabilitation in Schizophrenia: Does Cognitive Impairment Limit Improvement?
Bell, M. D., & BRYSON, G. J. (2001) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006873 · Cited by 164
Resting Cerebral Glucose Metabolism in First-Episode and Previously Treated Patients With Schizophrenia Relates to Clinical Features
Gur, R. E. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950200047013 · Cited by 156
Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids
Diana, M., Melis, M., & Gessa, G. L. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00292.x · Cited by 155
Subtype Progression and Pathophysiologic Deterioration in Early Schizophrenia
McGlashan, T. H., & Fenton, W. S. (1993) · Schizophrenia Bulletin · doi:10.1093/schbul/19.1.71 · Cited by 152
Natural History of Schizophrenia Subtypes
Fenton, W. S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810350009002 · Cited by 151
Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?
Sharp, F. R., Tomitaka, M., Bernaudin, M., & Tomitaka, S. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01817-8 · Cited by 151
Δ9-Tetrahydrocannabinol Acts as a Partial Agonist to Modulate Glutamatergic Synaptic Transmission between Rat Hippocampal Neurons in Culture
Shen, M., & Thayer, S. A. (1999) · Molecular Pharmacology · doi:10.1124/mol.55.1.8 · Cited by 150
Carbamazepine and Haloperidol v Placebo and Haloperidol in Excited Psychoses
Klein, E. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790130061009 · Cited by 150
Changes in Serotonin2A and GABAA Receptors in Schizophrenia
Dean, B., Hussain, T., Hayes, W., Scarr, E., Kitsoulis, S., Hill, C., Opeskin, K., & Copolov, D. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.721593.x · Cited by 148
Chapter 28 The glutamate synapse in neuropsychiatric disorders: Focus on schizophrenia and Alzheimer's disease
Farber, N. B., Newcomer, J. W., & Olney, J. W. (1998) · Progress in brain research · doi:10.1016/s0079-6123(08)60453-7 · Cited by 148
Glutamatergic Regulation of Basal and Stimulus‐Activated Dopamine Release in the Prefrontal Cortex
Takahata, R., & Moghaddam, B. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71041443.x · Cited by 144
[3H]Muscimol binding sites increased in autopsied brains of chronic schizophrenics
Hanada, S., Mita, T., Nishino, N., & Tanaka, C. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90341-9 · Cited by 140
Increased Vertical Axon Numbers in Cingulate Cortex of Schizophrenics
Benes, F. M. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800230097015 · Cited by 140
Effect of Clozapine and Adjunctive High-Dose Glycine in Treatment-Resistant Schizophrenia
Potkin, S. G., Jin, Y., Bunney, B. G., COSTA, J. F., & Gulasekaram, B. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.145 · Cited by 139
Voltage‐Activated Calcium Channels: Targets of Antiepileptic Drug Therapy?
Stefani, A., Spadoni, F., & Bernardi, G. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01477.x · Cited by 138
Diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (1H MRS) in schizophrenic subjects and normal controls
Steel, R. M., Bastin, M. E., McConnell, S., Marshall, I., Owens, D. G. C., Lawrie, S. M., Johnstone, E. C., & Best, J. J. K. (2001) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(01)00080-4 · Cited by 138
Biexponential kinetics of [3H]MK-801 binding: evidence for access to closed and open N-methyl-D-aspartate receptor channels.
Javitt, D. C., & Zukin, S. R. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)11243-1 · Cited by 133
Involvement of γ-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex
Yonezawa, Y., Kuroki, T., Kawahara, T., Tashiro, N., & Uchimura, H. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01435-0 · Cited by 133
Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic caseseries outcome study
Dursun, S. M., & Deakin, J. F. W. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500409 · Cited by 125
Control of Feedforward Dendritic Inhibition by NMDA Receptor-Dependent Spike Timing in Hippocampal Interneurons
Maccaferri, G., & Dingledine, R. J. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05462.2002 · Cited by 124
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity
Farber, N. B., Kim, S. H., Dikranian, K. T., Jiang, X. P., & Heinkel, C. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4000912 · Cited by 122
The role of N-Methyl-D-Aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes
Heresco‐Levy, U., & Javitt, D. C. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)00050-3 · Cited by 121
Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones
Wang, S., Huang, C., Hsu, K., Tsai, J.-J., & Gean, P. (1996) · Neuroreport · doi:10.1097/00001756-199611250-00048 · Cited by 121

Sorted by citations

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons and Pyramidal Neurons
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231
The role of default network deactivation in cognition and disease
Anticevic, A., Cole, M. W., Murray, J. D., Corlett, P. R., Wang, X.-J., & Krystal, J. H. (2012) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2012.10.008 · Cited by 978
Self-citation
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Neuromodulation of thought: flexibilities and vulnerabilities in prefrontal cortical network synapses
Arnsten, A. F. T., Wang, M. J., & Paspalas, C. D. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.038 · Cited by 538

See all 530

Authors: Krystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R.
Affiliations: VA Connecticut Healthcare System (US)
Yale University (US)
Yale New Haven Hospital (US)
Corresponding author: Krystal, John H.
ORCID: Krystal, John H.
Mathalon, Daniel
Venue: Psychopharmacology
Publisher: Springer Science and Business Media LLC
Published: 2003-09-01
Volume: 169
Issue: 3-4
Pages: 215-233
ISSN: 0033-3158 (ISSN-L)
1432-2072
DOI: 10.1007/s00213-003-1582-z
OpenAlex: W2020140782
Cited by: 530
References: 307
Citations by year: 2026: 11 · 2025: 10 · 2024: 11 · 2023: 16 · 2022: 11 · 2021: 15 · 2020: 20 · 2019: 19 · 2018: 24 · 2017: 27 · 2016: 28 · 2015: 28 · 2014: 20 · 2013: 33 · 2012: 40
FWCI: 11.05
Type: journal article
Language: en
Open access: green
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
Newcastle University ePrints (Newcastle Univesity)
Funders: National Institutes of Health (5k02aa000261-04)
National Institute on Alcohol Abuse and Alcoholism (K02 AA 00261-01)
National Institute of Mental Health (5P50 MH44866-12, P50MH044866)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: schizophrenia, NMDA receptor antagonists, ketamine, glutamatergic function, cortical connectivity, disinhibition, schizophrenia pharmacotherapy, cognitive impairment, translational neuroscience, antipsychotic drug development
MeSH terms: Animals, Cerebral Cortex, Cognition, Humans, Ketamine, Models, Neurological, Neural Pathways, Schizophrenia, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Glutamic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks